Remarkable response to neoadjuvant therapy with methotrexate, vinblastine, adriamycin, and cisplatin for undifferentiated bladder carcinoma: A case report and literature review

1Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a case of primary undifferentiated bladder carcinoma, which revealed a remarkable response to methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy. A 46-year-old Japanese woman presented at the hospital with the chief complaints of gross hematuria and pain during urination. Cystoscopy revealed a large smooth-surfaced tumor in the urinary bladder. The histopathological diagnosis was undifferentiated carcinoma. The patient then received 3 courses of MVAC over a 3-month period. Hydronephrosis disappeared after the first course, and the tumor shrank rapidly. After completion of the third MVAC course, radical cystectomy and ileal conduit surgery were performed. After 7 years, the patient has still had no recurrences or metastases. We retrospectively review the relative efficacy of the two popular chemotherapeutic regimens in the management of muscle-invasive bladder cancer in patients who had had radical cystectomy.

Cite

CITATION STYLE

APA

Numahata, K., Hoshi, S., Hoshi, K., Yasuno, N., Kubo, M., Sasagawa, I., & Ohta, S. (2014). Remarkable response to neoadjuvant therapy with methotrexate, vinblastine, adriamycin, and cisplatin for undifferentiated bladder carcinoma: A case report and literature review. Case Reports in Oncology, 7(3), 746–750. https://doi.org/10.1159/000369004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free